Inogen Inc (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $119,060. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of Inogen Inc (NASDAQ INGN) traded down $0.58 during trading on Wednesday, hitting $118.59. 195,745 shares of the company traded hands, compared to its average volume of 164,800. The company has a market cap of $2,460.00, a price-to-earnings ratio of 82.93, a price-to-earnings-growth ratio of 4.04 and a beta of 1.13. Inogen Inc has a 52 week low of $62.69 and a 52 week high of $130.05.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period in the prior year, the firm posted $0.25 EPS. Inogen’s revenue for the quarter was up 26.8% on a year-over-year basis. analysts predict that Inogen Inc will post 1.19 EPS for the current fiscal year.
Several brokerages recently issued reports on INGN. BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Leerink Swann reiterated an “outperform” rating and issued a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Piper Jaffray Companies reiterated a “hold” rating and issued a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Needham & Company LLC increased their price target on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 8th. Finally, Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a research note on Thursday, November 9th. Four equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $103.14.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.